Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 11;6:e2200010. doi: 10.1200/PO.22.00010

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

PMC Copyright notice

FIG 1. — (A) Patient 5-year DFS by clinical risk group/Immunoscore in patients with stage III colon cancer treated with adjuvant infusional fluorouracil, leucovorin, and oxaliplatin. Risk group is categorized as low-risk (T_1-3 N₁) or high-risk (T₄ and/or N₂), and Immunoscore is dichotomized as Immunoscore-Low or Immunoscore-High. Multivariable HRs and 95% CIs are shown. (B) Analysis was also performed with the study cohort restricted to cancers showing pMMR (DFS by risk group/Immunoscore [pMMR]). DFS, disease-free survival; Est, estimate; HR, hazard ratio; KM, Kaplan-Meier; pMMR, proficient mismatch repair.